Rapid Dose Therapeutics Corp. (RDTCF)
| Previous Close | 0.0151 |
| Open | 0.0151 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0151 - 0.0151 |
| 52 Week Range | 0.0021 - 0.2932 |
| Volume | |
| Avg. Volume | 12,151 |
| Market Cap | 19.137M |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Apr 29, 2024 - May 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Rapid Dose Therapeutics Reports Fiscal Year 2023 Financial Results
BURLINGTON, Ontario, June 28, 2023--Rapid Dose Therapeutics Corp. ("RDT" or the "Company") (CSE: DOSE), today reported its financial results for the year ended February 28, 2023.
- Business Wire
Rapid Dose Announces Increased Proposed Private Placement Financing of up to $5,000,000
BURLINGTON, Ontario, June 13, 2023--Rapid Dose Therapeutics Corp. ("RDT" or the "Company") (CSE: DOSE) today announced that further to its press release dated June 2, 2023, it plans to complete an increased private placement financing (the "Financing") for up to $5,000,000 of gross proceeds (an increase from $3,000,000), consisting of up to 5,000,000 units (the "Units") at a price of $1.00 per Unit. Each Unit will consist of $1.00 principal amount of secured convertible notes (the "Notes") and f
- Business Wire
Rapid Dose Announces Proposed Private Placement Financing
BURLINGTON, Ontario, June 03, 2023--Rapid Dose Therapeutics Corp. ("RDT" or the "Company") (CSE: DOSE) today announced that it plans to complete a private placement financing (the "Financing") for up to $3,000,000 of gross proceeds, consisting of up to 3,000,000 units (the "Units") at a price of $1.00 per Unit. Each Unit will consist of $1.00 principal amount of secured convertible notes (the "Notes") and five (5) common share purchase warrants of the Company (the "Warrants"). The Financing may
